1KO 1G3, n = 7; 1KO 5A4, n = 2; 1∆ 4B10, n = 5; 1∆ 3D8, n = 7; 1∆ 3G3, n = 10; 1∆ 4G6, n = 3; 3KO 2H2, n= 4; 3KO 6H6, n= 6; 3KO CI3, n= 3; 1+3KO 1G1, n = 3; 1+3KO 3D7, n = 8.
(B) Raw data of the poly(I:C)-mediated podocyte cell death measurements presented in Figs.
1C and Fig. S1A (ctrl= untreated control). Ctrl : WT, n = 15; 1KO 1G3, n = 14; 1KO 5A4, n = 6; 1∆ 4B10, n = 14; 1∆ 3D8, n = 12; 1∆ 3G3, n = 9; 1∆ 4G6, n = 12; 3KO 2H2, n= 16; 3KO 6H6, n= 28; 3KO CI3, n= 9; 1+3KO 1G1, n = 6; 1+3KO 3D7, n = 16. Poly(I:C) :
WT, n = 18; 1KO 1G3, n = 14; 1KO 5A4, n = 6; 1∆ 4B10, n = 14; 1∆ 3D8, n = 12; 1∆ 3G3, n = 9; 1∆ 4G6, n = 12; 3KO 2H2, n= 16; 3KO 6H6, n= 28; 3KO CI3, n= 9; 1+3KO 1G1, n = 8; 1+3KO 3D7, n = 16. (A) Specificity of the immunolabelling with the anti-APOL1 and anti-V5 antibodies, as revealed by the strong reduction of staining, particularly cytoplasmic, with the anti-APOL1 antibody in the APOL1KO or APOL1+3KO cells, and by the absence of staining with the anti-V5 antibody in non-V5 tagged WT cells. Anti-V5 antibodies label Cterminal V5-tagged APOL3.
(B) Immunofluorescence analysis of APOL1 and APOL3 co-localization. The graphs show the co-localization levels of cytoplasmic APOL1 and V5-APOL3, following removal of the APOL staining covered with the nuclear DAPI marker (error bars = SD). ctrl, n = 32; poly(I:C), n = 21.
(C) Immunofluorescence analysis of APOL1 and APOL3 distribution with respect to ER and trans-Golgi markers (Calnexin and Golgin97, respectively). The graphs show the colocalization levels of cytoplasmic APOLs with ER or trans-Golgi markers, following removal of the APOL staining covered with the nuclear DAPI marker (error bars = SD).
CytAPOL1/ Calnexin panel : ctrl, n = 30; poly(I:C), n = 24. CytAPOL1/ Golgin97 panel :
ctrl, n = 23; poly(I:C), n = 23. CytAPOL3/ Calnexin panel : ctrl, n = 33; poly(I:C), n = 23.
CytAPOL3/ Golgin97 panel : ctrl, n = 23; poly(I:C), n = 24.
Cells were randomly selected from 3 independent experiments (ctrl = untreated cells; n = nucleus; scale bars = 20 µm). In all images, the nuclear and cellular contours are indicated by dotted lines; when absent, these contours are outside the image surface. In the APOL1 and APOL3 sequences, the coloured sections were edited in different podocyte cell lines as shown in the table. P35579  216 kDa  28  89  11  25  33  88  7  85  MYO6  Q9UM54  145 kDa  0  36  0  0  0  17  0  11  MYO1C  O00159  122 kDa  4  18  0  2  4  9  0  5  Gelsolin  B7Z6N2  85 kDa  2  17  0  0  8  11  0  10  Drebrin  Q16643  71 Left panels illustrate clustered labelling close to the mitochondrion (m = mitochondrion); panels at the right exhibit cytosolic labelling. Bars = 200 nm.
(B) Western blot analysis of APOL1 in either normal human serum (NHS) (0.2 µl) or WT podocytes extracts (10 µg). NHS was added to extracts from either 1KO or WT podocytes to avoid any electrophoretic mobility difference linked to differential protein loading, also allowing the demonstration that intracellular APOL1 (arrow) migrates between the two APOL1 bands in NHS.
(C) qRT-PCR analysis of APOL1 isoforms (means +/-SD; n = 3).
(D) Prediction of signal peptide in APOL1 isoform 3, using the SignalP-5.0 program (Expasy).
(E) Comparison of the predicted cleavage sites in WT APOL1 (blue) or isoform 3 (green). (B) BLI measurements of interaction between bound NCS-1 and APOL3, in the presence or not of WT or mutant NCS-1 in a molar ratio of 1:2 (APOL3 : NCS-1) (n = 3).
(C) BLI measurements of interaction between bound NCS-1 and various concentrations of APOL3, with fitted curves (red) for determination of APOL3/NCS-1 binding affinity (n = 3).
(D) Generation of N-myristoylated NCS-1. Recombinant NCS-1 was synthesized in E. coli together or not with human N-myristoyl-transferase (hsNMT1) and either myristic acid or its alkynyled analogue 13-tetradecynoic acid. Fluorescent N-myristoylated NCS-1 was detected by binding of the TAMRA fluorophore to NCS-1-bound 13-tetradecynoic acid.
Coomassie blue staining allows detection of NCS-1 (arrowhead), in total E. coli extracts or purified recombinant protein fraction.
(E) BLI measurements of interaction between bound N-myristoylated NCS-1 and APOL3 or PI4KB, added sequentially as indicated (n = 3).
(F) BLI measurements of interaction between bound NCS-1 and various APOLs, added sequentially as indicated (n = 3).
(G) BLI measurements of interaction between bound NCS-1 and APOL3, alone or with different molar ratios of G1 or G2 (n = 3).
All quantitative measurements are expressed as means +/-SD. 2016) and synthesizes PI(4)P that is crucial for secretion (Bishé et al., 2012; de Barry et al., 2006; Dippold et al., 2009; Haynes et al., 2005; Kuna and Field, 2019; Tokuda et al., 2014; Zhao et al., 2001) . The N-myristoylated form of NCS-1 activates PI4KB through a direct interaction (Zhao et al., 2001) . APOL3 interacts with NCS-1 irrespective of NCS-1 myristoylation, through Ca 2+ -dependent hydrophobic contacts involving its C-terminal hydrophobic cluster. These contacts evoke those between the yeast NCS-1 homologue Frq1 and the PI4KB homologue Pik1 (Pandalaneni et al., 2015; Strahl et al., 2003) .
Whereas APOL1 or APOL1 G1/G2 variants can hinder association of APOL3 with NCS-1 (dotted or plain red line respectively), APOL1∆ can bind to APOL3 and inactivate this protein without dissociating the APOL3/NCS-1 complex. In APOL1∆ and APOL3KO cells where APOL3 is no longer active, PI4KB is inhibited and the level of Golgi PI(4)P is reduced. However, in the absence of both APOL1 and APOL3, PI4KB appears to be active. In addition to the control of PI4KB, APOL1 and APOL3 also influence the levels of Ca 2+ in Golgi stores, possibly through their redundant K + channel activity. Hypotheses attempting to explain these observations are presented in the discussion (CALN = PI4KB inhibitor calneuron).
(B) Interplay between APOLs, PI(4)P and the NM2A myosin. APOL1 and APOL3 bind to and co-localize with PI(4)P, and indirectly associate with the fission and secretion motor NM2A. Multiple pathways connect PI(4)P with NM2A. In particular, (i) the PI(4)Pbinding protein GOLPH3 binds to the NM2A-interacting protein MYO18A (Billington et
